Predictive factors related to clinical response in patients with metastatic melanoma treated with dendritic cell based immunotherapy.

Project Details

Description

Recently obtained results from different clinical trials indicate that new modalities of specific immunotherapy are active in the treatment of the patients with melanoma and other cancers. During the past 5 years our research group has conducted institutional pilot trials on therapeutic vaccination of melanoma patients with autologous dentritic cell vaccines. We believe that there are two major strategies that can help to improve the clinical efficacy of specific immunotherapy. Firstly, through better knowledge of the immunosuppressive mechanism mediating tumour-resistance at the time of therapeutic vaccination and subsequent development of therapeutic vaccination in order to induce more efficient anti-cancer T cell clones. This project proposal aims at progressing towards these improvements by investigating three types of predictive biological markers: markers of baseline immune competence and cancer associated mechanisms of immunosuppression, and markers of vaccine efficacy. The study of these markers will be performed on the archival cellular material from patients treated in our completed clinical trials and prospectively collected in the ongoing and planned clinical trials with dendritic cell vaccination for advanced melanoma.
AcronymANI61
StatusFinished
Effective start/end date1/09/0931/08/12

Keywords

  • Tonic Pain
  • Dendritic Cells
  • Evoked Potentials
  • Bispecific Antibodies
  • Immunotherapy
  • Immunology
  • Oncology

Flemish discipline codes

  • Basic sciences
  • Biological sciences
  • Materials engineering